LAS VEGAS—As America remains gripped by the opioid crisis, with 106,000 opioid-related deaths in 2022, drug companies look for new agents designed to deter abuse while effectively managing pain.
To this end, Ensysce Biosciences Inc., a clinical-stage pharmaceutical company in La Jolla, Calif., presented two studies examining the safety and effectiveness of two “next-generation” analgesics, PF614 and PF614-MPAR (multi-pill abuse resistance), at the 2023 annual PAINWeek